Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Contact information

Email
alison.lawrie@ndm.ox.ac.uk

Research groups

Alison Lawrie

Senior Vaccine Development Co-ordinator & Head of Regulatory Affairs

Recent publications

Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial

Silk SE. et al, (2024), The Lancet Infectious Diseases, 24, 1105 - 1117

Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial

Datoo MS. et al, (2024), The Lancet, 403, 533 - 544

Superior antibody immunogenicity of a viral-vectored RH5 blood-stage malaria vaccine in Tanzanian infants as compared to adults

Silk SE. et al, (2023), Med, 4, 668 - 686.e7

Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection

Hou MM. et al, (2023), Science Translational Medicine, 15

ee-antigen Plasmodium falciparum DNA prime—Adenovirus boost malaria vaccine regimen is superior to a two-antigen regimen and protects against controlled human malaria infection in healthy malaria-naïve adults

Sklar MJ. et al, (2021), PLOS ONE, 16, e0256980 - e0256980